Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 5, 1998, Pages 561-570

  Inoue, Tomoo ^b   Ohnishi, Akihiro ^a   Matsuo, Atsushi ^b   Kawai, Bunpei ^b   Kunihiro, Naoko ^b   Tada, Yoshiki ^b   Koizumi, Fumiaki ^b   Chau, Tommy ^b   Okada, Keizo ^b   Yamamura, Yoshitaka ^b   Tanaka, Teruji ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MOZAVAPTAN; PROSTAGLANDIN E2; SODIUM ION; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG MECHANISM; EDEMA; FEMALE; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; POWDER; PRIORITY JOURNAL; URINARY EXCRETION; VIRUS HEPATITIS; WATER RETENTION;

ADMINISTRATION, ORAL; ADULT; AGED; ARGININE VASOPRESSIN; BENZAZEPINES; DINOPROSTONE; DIURESIS; ELECTROLYTES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, VASOPRESSIN;

EID: 13144266671     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90107-2     Document Type: Article

References (28)

1. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-7.
2. Vaamonde CA. Renal water handling in liver disease. In: Epstein M, editor. The kidney in liver disease. 4th ed. Philadelphia: Hanley & Belfus; 1996. p. 33-74.
3. Clária J, Jiménez W, Arroyo V, Guarner F, López C, Villa GL, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989;97:1294-9.
4. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988;319:1058-64 [part 1]; 1127-34 [part 2].
5. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988;319:1058-64 [part 1]; 1127-34 [part 2].
6. Padfield PL, Morton JJ. Application of a sensitive radioimmunoassay for plasma arginine vasopressin to pathological conditions in man. Clin Sci Mol Med 1974;47:16P-7P.
7. Reznick RK, Langer B, Taylor BR, Seif S, Blendis LM. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting. Gastroenterology 1983;84:713-8.
8. Arroyo V, Clária J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58.
9. Castellano G, Sólis-Herruzo JA, Morillas JD, Larrodera L, Cocca C, Gonzalez-Gamarra A, et al. Antidiuretic hormone and renal function after water loading in patients with cirrhosis of the liver. Scand J Gastroenterol 1991;26:49-57.
10. Ardaillou R, Benmansour M, Rondeau E, Caillens H. Metabolism and secretion of antidiuretic hormone in patients with renal failure, cardiac insufficiency, and liver insufficiency. Adv Nephrol 1984;13:35-49.
11. Brooks DP, Koster PF, Albrightson CR, Huffman WF, Moore ML, Stassen FL, et al. Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements. Eur J Pharmacol 1989;160:159-62.
12. Manning M, Przybylski JP, Olma A, Klis WA, Kruszynski M, Wo NC, et al. No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 1987;329:839-40.
13. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-91.
14. Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, et al. Potent aquaretic agent: a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-9.
15. Ohnishi A, Orita Y, Takagi N, Fujita T, Toyoki T, Ihara Y, et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995;272:546-51.
16. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994;46:237-44.
17. Campbell DP, Parker DE, Anagnostopoulos CE. Survival prediction in portocaval shunts, a computerized statistical analysis. Am J Surg 1973;126:748-51.
18. Ohnishi A, Murakami S, Harada M, Osaka K, Wada K, Odagiri M, et al. Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. J Hepatol 1994;20:223-30.
19. Madsen M, Pedersen EB, Danielsen H, Jensen LS, Sorensen SS. Impaired renal water excretion in early hepatic cirrhosis. Scand J Gastroenterol 1986;21:749-55.
20. 2 excretion, plasma arginine vasopressin, and renal water excretion after oral water loading in early hepatic cirrhosis. Eur J Clin Invest 1988;18:202-6.
21. Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984;26:72-80.
22. Kostreva DR, Castaner A, Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980;238:R390-4.
23. Lang F, Tschernenko E, Schulze E, Ottl I, Ritter M, Volkl H, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991;14:590-4.
24. Levy M, Wexler MJ. Sodium excretion in dogs with lowgrade caval constriction: role of hepatic nerves. Am J Physiol 1987;253:F672-8.
25. Handler JS. Vasopressin-prostaglandin interaction in the regulation of epithelial cell permeability to water. Kidney Int 1981;19:831-8.
26. Schedl HP, Bartter FC. An explanation for experimental correction of the abnormal water diuresis in cirrhosis. J Clin Invest 1960;39:248-61.
27. Epstein M, Pins DS, Schneider N, Levinson R. Determination of deranged sodium and water homeostasis in decompensated cirrhosis. J Lab Clin Med 1976;87:822-39.
28. Bichet DG, Groves BM, Schrier RW. Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients. Kidney Int 1983;24:788-94.